Four Top Psychedelic Stock Picks for 2021

ATLANTA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadruple.

Might a safer version of a psychedelic help treat depression?

Research in animals suggests that the new compound is neither toxic nor hallucinogenic and that it may help treat a range of psychiatric disorders, including depression and addiction, and possibly anxiety and post-traumatic stress disorder (PTSD).

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.

Psilocybin Could be Key to Helping Millions of People with Eating Disorders

With clinical trials supporting psychedelics, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.